Cargando…
Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil
SETTING: Patients HIV+ attending in a reference clinic, Southern Brazil. OBJECTIVE: To compare the interferon-gamma-release assay (IGRA – QuantiFERON(®) TB Gold In-Tube) with the tuberculin skin test (TST – PPD-Rt 23) for latent tuberculosis infection (LTBI) in patients with HIV. DESIGN: Cohort stud...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425390/ https://www.ncbi.nlm.nih.gov/pubmed/26706018 http://dx.doi.org/10.1016/j.bjid.2015.10.007 |
_version_ | 1784778438416007168 |
---|---|
author | Kussen, Gislene Maria Botão Dalla-Costa, Libera Maria Rossoni, Andrea Raboni, Sonia Mara |
author_facet | Kussen, Gislene Maria Botão Dalla-Costa, Libera Maria Rossoni, Andrea Raboni, Sonia Mara |
author_sort | Kussen, Gislene Maria Botão |
collection | PubMed |
description | SETTING: Patients HIV+ attending in a reference clinic, Southern Brazil. OBJECTIVE: To compare the interferon-gamma-release assay (IGRA – QuantiFERON(®) TB Gold In-Tube) with the tuberculin skin test (TST – PPD-Rt 23) for latent tuberculosis infection (LTBI) in patients with HIV. DESIGN: Cohort study. Patients were simultaneously submitted to the TST and blood collection for the IGRA. RESULTS: A total of 140 subjects were included. Nine (6.4%) were IGRA+/TST+, 12 (8.6%) were IGRA+/TST−, 4 (3%) were IGRA−/TST+, and 115 (82%) IGRA−/TST−. There was poor agreement between tests (kappa = 0.2), and no correlation between these results and CD4+ T lymphocyte counts. During follow-up, one patient with negative results on both tests died from sepsis, and another with discordant results (IGRA+/TST−) exhibited TST seroconversion. Compared to the TST, IGRA showed a sensitivity and specificity of 69% and 90%, respectively. The IGRA detected 8% more positive results than the TST. All patients were followed up for 2 years. CONCLUSION: The higher accuracy of the IGRA would result in LTBI treatments being administered to patients who would have otherwise been overlooked, decreasing the number of active tuberculosis cases. The long-term survival of HIV carriers requires further evaluation. |
format | Online Article Text |
id | pubmed-9425390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94253902022-08-31 Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil Kussen, Gislene Maria Botão Dalla-Costa, Libera Maria Rossoni, Andrea Raboni, Sonia Mara Braz J Infect Dis Original Article SETTING: Patients HIV+ attending in a reference clinic, Southern Brazil. OBJECTIVE: To compare the interferon-gamma-release assay (IGRA – QuantiFERON(®) TB Gold In-Tube) with the tuberculin skin test (TST – PPD-Rt 23) for latent tuberculosis infection (LTBI) in patients with HIV. DESIGN: Cohort study. Patients were simultaneously submitted to the TST and blood collection for the IGRA. RESULTS: A total of 140 subjects were included. Nine (6.4%) were IGRA+/TST+, 12 (8.6%) were IGRA+/TST−, 4 (3%) were IGRA−/TST+, and 115 (82%) IGRA−/TST−. There was poor agreement between tests (kappa = 0.2), and no correlation between these results and CD4+ T lymphocyte counts. During follow-up, one patient with negative results on both tests died from sepsis, and another with discordant results (IGRA+/TST−) exhibited TST seroconversion. Compared to the TST, IGRA showed a sensitivity and specificity of 69% and 90%, respectively. The IGRA detected 8% more positive results than the TST. All patients were followed up for 2 years. CONCLUSION: The higher accuracy of the IGRA would result in LTBI treatments being administered to patients who would have otherwise been overlooked, decreasing the number of active tuberculosis cases. The long-term survival of HIV carriers requires further evaluation. Elsevier 2015-12-17 /pmc/articles/PMC9425390/ /pubmed/26706018 http://dx.doi.org/10.1016/j.bjid.2015.10.007 Text en © 2015 Elsevier Editora Ltda. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Kussen, Gislene Maria Botão Dalla-Costa, Libera Maria Rossoni, Andrea Raboni, Sonia Mara Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title | Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title_full | Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title_fullStr | Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title_full_unstemmed | Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title_short | Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil |
title_sort | interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among hiv patients in brazil |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425390/ https://www.ncbi.nlm.nih.gov/pubmed/26706018 http://dx.doi.org/10.1016/j.bjid.2015.10.007 |
work_keys_str_mv | AT kussengislenemariabotao interferongammareleaseassayversustuberculinskintestforlatenttuberculosisinfectionamonghivpatientsinbrazil AT dallacostaliberamaria interferongammareleaseassayversustuberculinskintestforlatenttuberculosisinfectionamonghivpatientsinbrazil AT rossoniandrea interferongammareleaseassayversustuberculinskintestforlatenttuberculosisinfectionamonghivpatientsinbrazil AT rabonisoniamara interferongammareleaseassayversustuberculinskintestforlatenttuberculosisinfectionamonghivpatientsinbrazil |